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Abstract  
Current pharmacological treatments for insomnia include benzodiazepine and non-
benzodiazepine hypnotics targeting GABAA receptors, as well as agonists of the melatonin 
receptors MT1 and MT2. Melatonin, temazepam and zolpidem are thought to exert their 
effect through different mechanisms of action, but whether this leads to differential effects on 
EEG power spectra during sleep in middle-aged people is currently not known.  To establish 
whether the effects of prolonged-release melatonin (2mg) on the nocturnal sleep EEG are 
different to those of temazepam (20mg) and zolpidem (10mg). Sixteen healthy men and 
women aged 55-64 years participated in a double-blind, placebo-controlled, four-way cross-
over trial. Nocturnal sleep was assessed with polysomnography and spectral analysis of the 
EEG. The effects of single oral doses of prolonged-release melatonin, temazepam and 
zolpidem on EEG slow-wave activity (SWA, 0.75-4.5Hz) and other frequencies during 
nocturnal non-REM (NREM) sleep were compared. In an entire night analysis prolonged-
release melatonin did not affect SWA, whereas temazepam and zolpidem significantly 
reduced SWA compared with placebo. Temazepam significantly reduced SWA compared 
with prolonged-release melatonin. Prolonged-release melatonin only reduced SWA during 
the first third of the night compared with placebo. These data show that the effects of 
prolonged-release melatonin on the nocturnal sleep EEG are minor and are different from 
those of temazepam and zolpidem; this is likely due to the different mechanisms of action of 
the medications. 
 
Introduction 
Insomnia is common in many psychiatric disorders and also in older people (Riemann et al., 
2011).  Pharmacological treatment options for insomnia include benzodiazepine and non-
benzodiazepine hypnotics that target GABAA receptors and other hypnotics including 
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melatonin receptor agonists (Ebert et al., 2006; Rudolph and Knoflach, 2011), the latter of 
which are sometimes referred to as chronobiotics. Current understanding of the 
neurochemical basis of sleep regulation provides a rational basis for pursuing both 
mechanisms of action (Saper et al., 2005). There is considerable evidence for a role of the 
wide range of GABAA receptor subtypes in sleep regulation (Lancel, 1999; Winsky-
Sommerer, 2009). The classical benzodiazepine temazepam targets the majority of GABAA 
receptor subtypes in an unspecific manner, whereas the widely prescribed imidazopyridine 
zolpidem displays some selectivity for GABAA receptors containing the alpha-1 subunit.   
 
Evidence for a role of melatonin in sleep regulation consists of the close association between 
the endogenous circadian rhythm of melatonin secretion and the sleep propensity rhythm, as 
well as specific EEG characteristics such as sleep spindle activity (Cajochen et al., 2003; Dijk 
et al., 1997). Sleep scheduled outside the phase of nocturnal melatonin secretion is disrupted 
and characterised by delayed sleep initiation and reduced sleep consolidation, and this can be 
alleviated by exogenous melatonin administration, and several studies have demonstrated this 
in healthy individuals (Rajaratnam et al., 2004; Stone et al., 2000; Wyatt et al., 2006). The 
effects of melatonin are thought to be mediated primarily by MT1 and MT2 receptors, which 
have a high density in the suprachiasmatic nucleus of the hypothalamus, amongst other areas 
(Arendt and Rajaratnam, 2008; Srinivasan et al., 2009). The different mechanisms of action 
of temazepam, zolpidem and prolonged-release melatonin could lead to differential effects on 
sleep structure and the sleep EEG, some of which may be undesirable. Effects on sleep 
structure may include reduced  time spent in slow-wave sleep (SWS),  which has been 
reported following benzodiazepines but not after zolpidem (Lancel, 1999; Winsky-
Sommerer, 2009), or melatonin (Srinivasan et al., 2009). SWS is defined on the basis of the 
presence of slow waves (< 2 Hz) with an amplitude exceeding 75µV.  
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Spectral analysis by Fast Fourier Transform (FFT) provides a description of the sleep EEG by 
computing power density (square of the amplitude, with no minimum amplitude criterion) 
within defined frequency ranges. Changes in the slow frequency range of the EEG after non-
pharmacological (Dijk et al., 1990a; Dijk et al., 1990b; Aeschbach et al., 1997) and 
pharmacological manipulations (Aeschbach et al., 1994) have been quantified by computing 
Slow Wave Activity (SWA), defined as power density in the 0.75-4.5Hz range. Spectral 
analysis of the EEG often confirms results of visual scoring of SWS, but may be more 
sensitive in assessing acute drug effects (Luthringer et al., 1995) as well as their chronic 
effects (Bastien et al., 2003) and also provides a description of changes in other frequencies. 
Sometimes dissociations between visual scoring and spectral analyses have been observed 
(Dijk et al., 1990a). In healthy individuals temazepam reduces visually scored SWS, SWA 
and theta activity, whilst enhancing spindle activity (Dijk et al., 1989).  Zolpidem on the 
other hand, leads to no change, or an increase in SWS, while at the same time it reduces 
SWA and theta/alpha activity, and enhances spindle activity (Bettica et al., 2012; Brunner et 
al., 1991; Walsh et al., 2007).  The effects of melatonin on the sleep EEG are equivocal. 
Administration of melatonin prior to daytime sleep causes no change in SWS, enhances 
spindle activity, but sometimes some reduction of SWA is observed in healthy individuals 
(Aeschbach et al., 2009; Dijk et al., 1995). Melatonin administration  to healthy individuals 
prior to nocturnal sleep did not lead to significant changes in either visually scored SWS or in 
the spectral composition of the sleep EEG (Cajochen et al., 1997), and an absence of changes 
in the sleep EEG was observed also following a prolonged-release formulation in elderly 
insomnia patients (Luthringer et al., 2009).  
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The efficacy of prolonged-release melatonin in the treatment of the subjective complaint of 
insomnia has been reported (Lemoine et al., 2007; Lemoine et al., 2011; Lemoine and 
Zisapel, 2012; Wade et al., 2007; Wade et al., 2010; Wade et al., 2011). However, we are not 
aware of any published studies that have directly compared the effects of a benzodiazepine, a 
non-benzodiazepine and prolonged-release melatonin on the sleep EEG. A prolonged-release 
formulation of melatonin (CIRCADIN®, RAD Neurim Pharmaceuticals EEC Ltd, Reading, 
UK) has been approved for the treatment of insomnia in people aged ≥55 years. Very few 
data on the effects of hypnotics on the spectral composition of the EEG are available for this 
age group and we are not aware of any studies of the effects of melatonin on the spectral 
composition of the sleep EEG in this age group.  We therefore investigated the acute effects 
of prolonged-release melatonin, temazepam and zolpidem on the spectral composition of the 
EEG during nocturnal sleep in healthy individuals aged 55-64 years. In view of the 
continuing interest in the functional significance of SWS (Dijk, 2010), the primary objective 
was to compare the EEG power spectra during NREM sleep in the slow-wave frequencies 
following a single dose of prolonged-release melatonin to a single dose of temazepam, and 
secondary objectives were to compare to a single dose of zolpidem or placebo. Other 
secondary objectives were to compare the effects of treatment on EEG power spectra during 
NREM and REM sleep in all EEG frequencies up to 32Hz. The EEG power density spectra 
during NREM sleep following prolonged-release melatonin was compared to temazepam, 
zolpidem and placebo in other traditional EEG frequency bands as an exploratory measure. 
Other exploratory objectives were to compare Polysomnography (PSG) and subjective sleep 
quality measures following prolonged-release melatonin to temazepam, zolpidem and 
placebo.  
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Methods 
Ethics 
The protocol was reviewed by and independent Ethics committee (Brent Medical Ethics 
Committee / NHS National Research Ethics Service) and was approved on the 20
th
 March 
2009 and a Clinical Trials Authorisation was provided by the Medicines and Healthcare 
products Regulatory Agency (MHRA). The study was conducted at the Surrey Clinical 
Research Centre (Surrey CRC) of the University of Surrey in accordance with principles 
based upon the Declaration of Helsinki and Good Clinical Practice. Written informed consent 
was obtained from all subjects prior to any study specific procedures. This study was 
sponsored by the University of Surrey and registered at Clinicaltrials.gov: NCT00940550. 
 
Subjects 
Subjects were recruited via the Surrey CRC database and through advertisements in the 
media. Study recruitment commenced in July 2009 and the last subject last visit was in 
August 2009. Fifty-two healthy men and women aged 55-64 years were medically screened 
for eligibility, of which 36 were excluded due to screening failure. Sixteen healthy men and 
women (12 men; mean age 58.8 years, SD 2.9), were enrolled in the study and were paid for 
their participation. Subjects had no sleep complaints and were judged healthy by physical 
examination, 12 lead ECG, medical and psychiatric history, haematology and clinical 
chemistry. Other key inclusion criteria included a regular sleep-wake cycle with a bedtime 
between 22:00h and 00:00h on at least 5 nights per week, reported typical sleep duration of 
6.5-8.5h and being a non-smoker. Exclusion criteria included being of childbearing potential; 
a known sensitivity to temazepam, zolpidem, or melatonin; Body Mass Index (BMI) <19 or 
>33kg/m
2
; a score >5 on the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989); a 
history of clinically significant sleep pathology according to DSM-IV-TR
®
 or an Apnea-
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Hypopnea Index (AHI) >10 or a Periodic Limb Movements Arousal Index (PLMAI) >10 as 
assessed at the clinical PSG screening visit. Other exclusion criteria included being a shift 
worker; having recently travelled through more than 2 time zones; drinking more than 5 
caffeinated beverages per day or consuming more than 3 (men) or 2 (women) units of alcohol 
per day; use of psychotropic medications and other medication that may interfere with of the 
study medications . 
 
Study Design 
A single centre, randomized, double-blind, placebo-controlled four-way crossover trial to 
study the effects of prolonged-release melatonin, temazepam and zolpidem on the spectral 
composition of the EEG during nocturnal sleep in healthy middle-aged men and women. 
Visit 1: General medical screening visit occurred up to 28 days prior to the first treatment 
visit and written informed consent was obtained. The visit included assessment of general 
health by history and examination, bloods for haematology, biochemistry and serology. 
Urinary screening for drugs of abuse and an alcohol breath test were performed. For females 
a pregnancy test was also required. Subjects received actiwatches (Actiwatch
®
, Cambridge 
Neurotechnology Ltd) to document the regularity of their sleep-wake schedules for the 
duration of the study, ensuring participants remained compliant with the inclusion criteria 
(bedtime between 22:00h and 00.00h on at least 5 out of 7 nights per week, including the 
night before a study visit and a sleep duration of between 6.5h and 8.5h). Visit 2: Adaptation 
and clinical PSG screening visit occurred at least 2 days prior to the first treatment visit. 
Subjects arrived at the Centre at ~17:00h. Medical status, concomitant medications and 
actigraphic recordings of sleep-wake schedules were reviewed and drug screening and 
alcohol breath tests were performed. Lights out was from 23:00-07:00h and PSG was 
recorded during this time. Blood samples (20:00, 21:00, 22:00, 23:00, 02:00, 05:00 and 
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08:00h) and pooled urine (19:00-21:00h, 21:00-23:00h, and 23:00-07:00h, with scheduled 
bladder voids at 20:30, 22:30 and 07:00h) was collected to assess subjects’ plasma melatonin 
profile and urinary 6-sulphatoxymelatonin excretion. The Karolinksa Sleepiness Scale (KSS) 
a 9-point Likert scale used to assess subjective sleepiness in the immediately preceding 
period (Akerstedt and Gillberg, 1990), was completed at 20:00, 22:00 and at 07:15h. The 
Sleep Quality Questionnaire (SQQ) comprising 10 questions regarding the previous nights’ 
sleep was completed shortly after awakening to assess subjective sleep quality. Visits 3-6: 
(Treatment periods (TPs) 1-4) Subjects arrived at the Centre at ~17:00h. Procedures 
conducted as in visit 2 with exception of collection of blood samples and with the addition of 
dosing with the study medications occurring at appropriate times before lights off. In order to 
allow for an adequate washout period between treatments, the TPs were separated by a 
minimum of 5 days. Lights out remained from 23:00-07:00h throughout the study. A post 
study telephone contact occurred after visit 6. Evening meals were served at 19:00 on all 
study visits and after that further food intake was not allowed. Safety: Adverse events were 
recorded and monitored from the time of the first dose of study medication until the follow up 
telephone contact.  
 
Study Medications, Doses and Timing of Administration     
Temazepam and zolpidem represent common choices in clinical practice for insomnia 
treatment. Doses of 20mg of temazepam and 10mg of zolpidem are indicated for insomnia in 
adults younger than 65 years. Prolonged-release melatonin 2mg is indicated for individuals 
≥55 years who suffer from insomnia. Therefore, the study population consisted of individuals 
aged 55-64 to assess and compare the influence of temazepam 20mg, zolpidem 10mg and 
prolonged-release melatonin 2mg on nocturnal sleep measured by EEG. Prolonged-release 
melatonin or matching placebo tablets were administered at 21:00h. Temazepam or zolpidem 
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or matching placebo capsules were administered at 22:45h. The difference in timing of 
administration of study drugs was to account for the differences in time to reach peak serum 
concentrations (CMAX), and therefore ensured that CMAX occurred at approximately the 
same time. The summary of product characteristics for prolonged-release melatonin indicates 
that CMAX is reached after approximately 3h in the fed state, whereas, temazepam and 
zolpidem reach CMAX quicker, after approximately 1h and 0.5-3h respectively.  All study 
medications and placebos were supplied by clinical supply management vendor Bilcare GCS 
(Europe) Ltd (Powys, UK). Prolonged-release melatonin 2mg tablets were sourced from H. 
Lundbeck A/S (Valby, Denmark) and matching placebo tablets were sourced from Penn 
Pharmaceutical Services Ltd (Gwent, Wales). Temazepam 10mg tablets and zolpidem 10mg 
tablets were sourced from Teva Pharmaceutical Industries Ltd (Eastbourne, UK) and were 
over-encapsulated by Bilcare GCS to produce temazepam 20mg and zolpidem 10mg capsules 
that were identical in appearance and matching placebo capsules were also supplied by 
Bilcare GCS. Tests were carried out by Bilcare GCS to confirm that over-encapsulated tablets 
complied with the pharmacopoeia standard for in vitro tablet disintegration. Any small delay 
in tablet disintegration caused by the over-encapsulation is not considered to have a 
significant effect on dissolution. We therefore can be confident that the pharmacodynamics 
and pharmacokinetics of study medications were not markedly affected by over-
encapsulation All study medications were administered at the recommended doses and 
frequency in accordance with applicable Summaries of Product Characteristics. Four 
treatment sequences were generated in a Latin square design. Bilcare GCS generated a 
randomisation list to ensure that subjects were randomized in balanced order to a treatment 
sequence (1:1:1:1 ratio) and packaged medications into treatment cartons according to the 
sequences and applied a randomized label to each. Subjects were assigned a randomisation 
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number at visit 3 (TP1) in sequential order. Both staff and subjects were blind to the study 
treatments until after data review and after the database was locked.   
 
PSG recordings and scoring of sleep stages 
Subjects slept in individual, sound attenuated, temperature controlled, windowless bedrooms. 
All PSGs were recorded on Siesta digital recorders (Compumedics, Abbotsford, Victoria, 
Australia) and the same recorder was used for each participant throughout the study. EEGs 
were recorded from C3-A2, C4-A1, O1-A2 and O2-A1 derivations, in addition to two 
submental electromyogram (EMG) and two electrooculogram (EOG) derivations. EEG 
signals were high pass filtered at 0.3Hz and low-pass filtered at 70Hz and these settings were 
appropriate for both visuals scoring and spectral analysis of the EEG. Sampling and storage 
rate was 256Hz for EEG, EOG and EMG signals. All PSG recordings were scored by 
Registered Polysomnographic Technologists (RPSGT’s) who were blinded to treatment. PSG 
recordings were scored per 30 second epochs, using ProFusion PSG software application 
within neXus Control (Compumedics Limited, Melbourne, Victoria, Australia). We used the 
standardised criteria of Rechtschaffen and Kales, to ensure compatibility with previous 
studies, sleep staged hypnograms were then exported to the data management database.  
 
EEG Spectral analysis 
Spectral analysis of EEG data recorded from 23:00-07:00h on each treatment night comprised 
the primary and secondary outcome measures of the study. PSG recordings were exported 
from the Compumedics system in EDF format and, together with the sleep staged 
hypnograms, were imported in Vitabase-Vitascore software, version 1.40 (RC.1) (Temec 
Instruments B.V., Kerkrade, The Netherlands). All sleep EEG data were visually inspected 
per 30 second epoch and artefacts were annotated manually by the first author (EA), within 
Melatonin, temazepam and zolpidem effects on sleep 
 
Page 11 of 29 
 
Vitascore software. Sub-epochs annotated as artefacts were excluded from the analysis of the 
power spectra. Spectral analysis was conducted using a Fast Fourier Transform (FFT). The 
data were weighted with a squared cosine window, implemented in the Vitascore software. 
Spectra were computed per 4-second sub-epoch, resulting in a 0.25Hz resolution up to 32Hz. 
In addition, power was computed in 8 traditional EEG frequency bands 0.25-<0.75Hz (low-
delta); 0.75-<4.75Hz (delta (SWA)); 4.75-<8.0Hz (theta); 8.0-<12.0Hz (alpha); 12.0-<15.0Hz 
(sigma); 15.0-<20.0Hz; 20.0-<25.0Hz; 25.0-<32.0Hz (beta-1, 2, 3 respectively). Sleep stage 
specific power spectra (stages 1, 2, 3, 4, NREM and REM) were computed for the entire 
night as well as per thirds of the night. All these computations were conducted in Vitascore 
software. One central derivation (C3-A2 in preference to C4-A1) was selected per participant, 
per visit, for analysis. We used the central derivation to ensure compatibility with previous 
studies.  The criteria set for the amount of sub-epochs of data remaining in the entire night for 
each derivation following artefact removal was 62.5%. Data reduction was achieved by 
computing power per 1Hz bin through addition of four consecutive 0.25Hz values and then 
dividing by the number of contributing 0.25Hz values. These data were then exported to the 
data management database.  
 
Statistical Approaches for Primary, Secondary and Exploratory Objectives 
A sample size of 15 was needed to detect, with a two-sided statistical test, at the 5% level of 
significance, with 80% power, a difference of 28% in suppression between prolonged-release 
melatonin 2 mg and temazepam 20 mg, assuming a between subject standard deviation of 
35%. Hence it was decided to recruit 16 subjects for this study. All statistical analyses were 
performed by Surrey CRC statisticians using SAS®, version 9.1 or later (SAS Institute Inc., 
Cary, NC) and all EEG power density values were log
10
 transformed prior to statistical 
analysis. The primary study objective was to compare EEG power spectra during NREM 
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sleep in the slow-wave frequencies following administration of prolonged-release melatonin 
2mg to temazepam 20mg, and secondary objectives were also to compare prolonged-release 
melatonin to zolpidem 10mg and placebo in the slow-wave frequencies. We conducted 
contrast analyses for four adjacent 1Hz bins (0.25-1.0, 1.25 to 2.0, 2.25 to 3.0, 3.25 to 4.0). 
To assess the robustness of the results we also investigated the effects on EEG activity in the 
slow-wave range by excluding the 0.25-1.0Hz range and including the 4.25 to 5.0Hz range 
(1.25-5.0Hz) The slow-wave frequency ranges were assessed by implementing SAS PROC 
MIXED with the REML option, with subject as random effect, with factors treatment 
(prolonged-release melatonin, temazepam, zolpidem and placebo), frequency bin (four 1Hz 
bins) and period (TP number), and including the condition by frequency bin interaction. This 
latter interaction allows for the assessment of any differential effects of treatment on 
particular frequencies within the slow-wave range. Frequency bin was used as a repeated 
measure with an unstructured variance-covariance matrix option. Using the LSMEANS 
statement of SAS PROC MIXED, the levels of treatment were statistically compared; 
estimates, unadjusted 95% confidence limits, and unadjusted P values were calculated and 
reported. In addition, Cohen’s d effect sizes were calculated from the mixed model results by 
taking the t value for the comparison of treatments, multiplying by 2, then dividing by the 
square root of the number of degrees of freedom in the t-test. Other secondary objectives 
included a comparison across conditions of EEG power spectra during NREM and REM 
sleep in all EEG frequencies between 0.25 and 32Hz, and due to limitations of mixed model 
estimation, geometric means of power densities within each treatment conditions were 
expressed relative to placebo (100%) and 95% confidence limits were used to compare the 
effects of treatment to placebo across the entire frequency spectrum. The 8 traditional EEG 
frequency bands, including the SWA range (0.75-4.5Hz), during NREM sleep were assessed 
as an exploratory objective across the entire night and per thirds of the night. The contrast 
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analyses for the 8 traditional bands were calculated using PROC MIXED as described above 
for the slow-wave frequencies, however, frequency bin was not used as a factor in the model 
and therefore no repeated statement was implemented in the model either. Exploratory 
analysis of PSG sleep measures and subjective sleep quality measures were conducted by 
calculating means and standard errors and implementing SAS PROC TTEST to calculate 
paired t-tests to compare treatment means. No multiplicity significance level adjustment was 
applied to the analyses concerning the secondary and exploratory endpoints.  
 
Results  
Subject disposition  
Sixteen subjects (14 White, 2 Black; 12 men; mean age 58.8 years, SD 2.9; mean BMI 25.6) 
were enrolled in the study and comprised the All Subjects Treated Set (ASTS). One subject 
did not attend one visit (TP3, treatment due to be administered at TP3 was administered at 
TP4, and the subject was subsequently withdrawn and therefore did not receive their final 
schedules treatment) and was excluded from the Per Protocol Set (PPS) (mean age and range 
as above). In three subjects some EEG recordings contained too many artefacts for a reliable 
assessment i.e. less than 62.5% of data remained following artefact removal; therefore six 
EEG recordings were also excluded from the PPS (2 x placebo and zolpidem nights and 1 x 
temazepam and prolonged-release melatonin nights). Data review and assignment to the PPS 
were completed prior to unblinding. Here we report data on the PPS. 
 
Plasma melatonin and 6-sulphatoxymelatonin 
Average plasma melatonin assessed at adaptation visit 2 rose early in the evening peaking at 
around 02:00h (see Figure 1). Assessment of subjects’ plasma melatonin profiles confirmed 
that no subjects were melatonin deficient. During treatment periods urinary excretion of 6-
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sulphatoxymelatonin increased with each pooled urine sample (19:00-21:00h, 21:00-23:00h, 
23:00-07:00h) (see Table 1). Compared to placebo, treatment with temazepam and zolpidem 
did not lead to differences in urinary 6-sulphatoxymelatonin, whereas treatment with 
prolonged-release melatonin caused a large increase in excretion of 6-sulphatoxymelatonin in 
all participants, which was evident in both the 21:00-23:00h and the 23:00-07:00h pooled 
urine samples. 
 
Slow-wave frequencies 
The primary and secondary study objectives were to compare the EEG power spectra during 
NREM sleep in the slow-wave frequencies following prolonged-release melatonin compared 
with temazepam, zolpidem and placebo. General linear mixed model analyses (see methods) 
with factors treatment (prolonged-release melatonin, temazepam, zolpidem, placebo), 
frequency bin (four consecutive 1Hz bins) and period (TP number), were performed over 
three NREM sleep frequency ranges to assess the robustness of the effects on the slow-wave 
frequencies. The slow-wave ranges analysed included 0.25-4.0Hz and 1.25-5.0Hz, each 
comprising four 1Hz bins. Additionally, mixed model analysis was performed with factors 
treatment and period for the traditional SWA band (0.75-<4.75Hz).  
 
We observed a significant effect of treatment and frequency bin in both the 0.25-4.0Hz and 
the 1.25-5.0Hz ranges, however, no significant interactions between treatment and frequency 
bin were observed (see Table 2). Following prolonged-release melatonin, activity was 
significantly higher in all three slow-wave ranges assessed compared with temazepam, but 
not compared with zolpidem or placebo (see Table 2 and Table 3). Temazepam suppressed 
activity in all three slow-wave ranges compared with placebo. Zolpidem supressed activity in 
the 1.25-5.0Hz and the traditional SWA ranges; but not the 0.25-4.0Hz range compared with 
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placebo (see Table 2 and Table 3). Compared with zolpidem, temazepam also significantly 
reduced activity in all three slow-wave ranges (see Table 2 and Table 3). Figure 2a displays 
power in the traditional SWA range following prolonged-release melatonin, temazepam and 
zolpidem administration relative to placebo for the entire night (see Figure 2). Effect sizes 
calculated based on Cohen’s d were all large except for the comparisons of prolonged-release 
melatonin with zolpidem in the 0.25-4.0Hz range and with placebo in the 1.25-5.0Hz range 
which produced the small and medium effect sizes respectively, these differences are likely 
due to the effect of zolpidem on the lowest 1Hz bin.  The effect sizes demonstrate that 
temazepam had the largest effect on the EEG compared with placebo and prolonged-release 
melatonin had the smallest.  
 
Traditional EEG frequency ranges  
As an exploratory measure the effect of treatment on NREM EEG power density within other 
traditional EEG ranges: 0.25-<0.75Hz (low-delta); 4.75-<8.0Hz (theta); 8.0-<12.0Hz (alpha); 
12.0-<15.0Hz (sigma); 15.0-<20.0Hz; 20.0-<25.0Hz; 25.0-<32.0Hz (beta-1, 2, 3 
respectively), was analysed in the same way as for the traditional SWA range (0.75-<4.75Hz 
(delta))  (see Table 3). Power density within the low-delta range was significantly lower 
following prolonged-release melatonin compared with zolpidem (P = 0.0007) and 
approached significance compared with temazepam (P = 0.0520). Please note that in this 
frequency range, values following zolpidem tended to be above placebo values (P = 0.0634), 
whereas for prolonged-release melatonin the values tended to be below placebo (P = 0.0779).  
Temazepam significantly decreased power within the SWA, theta and alpha ranges compared 
with prolonged-release melatonin and placebo. Zolpidem significantly decreased power 
within the theta and alpha ranges compared with prolonged-release melatonin and the SWA, 
Melatonin, temazepam and zolpidem effects on sleep 
 
Page 16 of 29 
 
theta and alpha ranges compared with placebo administration. Temazepam also significantly 
decreased activity in the SWA range when compared with zolpidem.  
 
The traditional EEG frequency ranges were also analysed per thirds of the night. Given that 
effects of temazepam and zolpidem on the EEG are typically reported for NREM sleep in the 
SWA and spindle frequency ranges, only these ranges are discussed here. Figures 2b, 2c and 
2d display power in the traditional SWA range following prolonged-release melatonin, 
temazepam and zolpidem administration relative to placebo for the first, second and last third 
of the night respectively (see Figure 2). NREM SWA significantly decreased following 
prolonged-release melatonin compared with placebo during the first third of the night (P = 
0.0093). Following temazepam SWA significantly decreased compared with placebo during 
all thirds of the night (P = 0.0237, <.0001, <.0001 respectively), and compared with 
prolonged-release melatonin and zolpidem during the second (P = <.0001, 0.0021 
respectively) and last (P = <.0001, 0.0025 respectively) thirds of the night. Following 
zolpidem SWA significantly decreased compared with placebo during the first and second 
thirds of the night (P = 0.0268, 0.0162 respectively), and compared with prolonged-release 
melatonin during the last third of the night (P = 0.0158). Following temazepam and zolpidem 
there was a significant increase in sigma activity (spindle frequency range) compared with 
prolonged-release melatonin (P = 0.0050, 0.0325 respectively) during the last third of the 
night.  
 
Power density spectrum 
Other secondary objectives were to assess the effects of treatment on the EEG power density 
up to 32Hz during NREM and REM sleep. Power spectra following treatment were expressed 
relative to placebo for the entire night (see Figure 3) and per thirds of the night during NREM 
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sleep for prolonged-release melatonin treatment (see Figure 4), and 95% confidence limits 
were used to indicate significant differences between treatment and placebo. Even though the 
interaction between treatment and frequency bin was not significant in either the 0.25-4Hz or 
1.25-5.0Hz range analyses, visual inspection of the EEG frequency spectrum (see Figure 3) 
suggests that the response to the various treatments was not uniform across the slow-wave 
frequencies during NREM sleep.  
 
Prolonged-release melatonin did not cause any marked changes to EEG power spectra during 
NREM or REM sleep compared with placebo. However, a small decrease in activity in the 
low-delta and SWA ranges was observed during the first third of the night (see Figure 4), as 
confirmed by analyses of traditional SWA range per thirds of the night (see above). 
Temazepam had the greatest effect on the lower frequencies during NREM sleep, and caused 
a substantial decrease in power up to approximately 10Hz compared with placebo, 
encompassing slow-wave, theta and low-alpha frequency ranges. Temazepam also marginally 
increased activity in the spindle frequency range at 12Hz compared with placebo. Zolpidem 
exerted similar effects to temazepam on NREM sleep; however, the decrease in activity in the 
slow-wave frequencies was less pronounced, and in the lowest 1Hz bin zolpidem increased 
power compared with placebo. The increase in power in the lowest bin following zolpidem 
reflects the significant increase in power following zolpidem compared with prolonged 
release melatonin observed in the low-delta band, which also approached significance 
compared with placebo. Compared with placebo, temazepam and zolpidem did not exert 
distinctive effects on the EEG power density spectra during REM sleep. 
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Visually scored PSG data 
Exploratory analyses included investigation of the effects of treatment on PSG measures by 
calculating paired t-tests (see Table 4). No significant effects of prolonged-release melatonin 
were observed for any of the visually scored PSG sleep variables when compared with 
placebo. Total Sleep Time (TST), duration of stage 2, duration of NREM sleep and sleep 
efficiency increased following temazepam and zolpidem compared with placebo and Wake 
After Sleep Onset (WASO) decreased. Additionally, temazepam significantly decreased 
number of awakenings (NAW), whilst Zolpidem significantly increased REM latency 
compared with placebo. TST, duration of stage 2, duration of NREM sleep and sleep 
efficiency were significantly higher and WASO was significantly lower following treatment 
with both temazepam and zolpidem, compared with prolonged-release melatonin. Duration of 
stage 1 and NAW were significantly lower following temazepam compared with prolonged-
release melatonin. Duration of stage 4 and stages 3+4 (SWS) were significantly higher and 
duration of REM was significantly lower following zolpidem compared with prolonged-
release melatonin. Stage 4 and NAW were significantly higher following zolpidem compared 
with temazepam.  
 
Subjective sleep quality 
Other exploratory analyses included comparisons of the effect of treatment on subjective 
sleep quality as assessed by the SQQ and the KSS, using paired t-tests. The question ‘How 
was the quality of your sleep last night?’ scored significantly better following temazepam and 
zolpidem compared with placebo (P = 0.0091, 0.0132 respectively) and prolonged-release 
melatonin (P = 0.0410, 0.0379 respectively). Subjects answered the question ‘How long did 
you sleep altogether?’ with significantly longer following temazepam compared with placebo 
and prolonged-release melatonin (P = 0.0173, 0.0308 respectively). The question ‘How many 
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times did you wake up?’ was answered with significantly fewer awakenings following 
temazepam compared with prolonged-release melatonin (P = 0.0281), and following 
zolpidem compared with placebo and prolonged-release melatonin (P = 0.0358, 0.0018 
respectively).  When asked ‘What was the total duration of those night awakenings’ subjects 
scored awakenings as significantly shorter following zolpidem compared with prolonged-
release melatonin (P = 0.0446). Assessment of sleepiness using the KSS scale did not reveal 
any significantly different scores between treatments at any time. 
 
Safety 
During the study conduct no deaths, serious adverse events or serious drug adverse reactions 
were reported and no participants were withdrawn from the study due to adverse event.  In 
total 48 adverse events were reported and the majority of the reports were mild in intensity. 
Out of 48 -39 adverse events were deemed by the investigator to be drug-related (placebo, 8; 
prolonged-release melatonin, 10; temazepam, 8; zolpidem, 13 events). The most widely 
reported adverse drug reactions (ADRs) under treatment with prolonged-release melatonin 
were gastro-intestinal disorder related which were reported for 4 subjects (constipation, dry 
mouth, flatulence and nausea). Additionally, 3 subjects reported nervous system disorder 
ADRs (balance disorder, somnolence and headache) and 2 subjects reported general disorders 
and administration site condition ADRs (fatigue and feeling hot) under treatment with 
prolonged-release melatonin. Under treatment with temazepam 5 subjects reported nervous 
system related ADRs (balance disorder, headache and somnolence). Additionally, gastro-
intestinal disorder related ADRs (dry mouth), and psychiatric disorder related ADRs 
(nightmare) were reported by 1 subject each, under treatment with temazepam. Two subjects 
reported nervous system related ADRs (balance disorder and headache) and 2 subjects 
reported ADRs relating to general disorders and administration site condition (asthenia and 
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thirst) under treatment with zolpidem. Other ADRs reported under treatment with zolpidem 
included gastro-intestinal disorders (nausea), and psychiatric disorders (anxiety and 
disorientation), each reported by 1 subject. It should also be noted that 6 subjects in total 
reported at least 1 ADR under the placebo condition. Two subjects reported renal and urinary 
disorder ADRs and 2 subjects reported nervous system disorder ADRs (dizziness and 
headache) under the placebo condition. In addition, gastro-intestinal disorder (dry mouth), 
psychiatric disorder (dissociation) and general disorder and administration site condition 
(fatigue) ADRs were reported by 1 subject each, under the placebo condition. No clinically 
significant influence of treatment was noted on vital signs and clinical laboratory values. 
Overall all study medications were well tolerated. 
 
Discussion 
The data demonstrate that single doses of temazepam, zolpidem and prolonged release 
melatonin exert differential effects on sleep and the EEG. The data show that evening 
administration of prolonged-release melatonin to older subjects, who are not melatonin 
deficient, has relatively minor effects on NREM slow-wave frequency ranges of the nocturnal 
EEG in comparison to those of temazepam and zolpidem. These findings are in accordance 
with previous studies which found no major effects of prolonged-release melatonin on the 
spectral composition of the nocturnal EEG in both healthy individuals (Cajochen et al., 1997) 
and insomnia patients (Luthringer et al., 2009). Other researchers have found that daytime 
administration of melatonin in healthy individuals induces effects on the EEG reminiscent of 
those induced by benzodiazepines and non-benzodiazepine z-drugs including a reduction in 
SWA and an increase in spindle activity (Aeschbach et al., 2009; Dijk et al., 1995), whereas 
in our study we observed that prolonged-release melatonin only suppressed SWA during the 
first third of the night. If we accept that the current and published data show that during the 
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night melatonin has at best minor effects on the EEG and that during the day melatonin 
affects the EEG then it may be hypothesized that effects of exogenous melatonin on the EEG 
are only observed when endogenous melatonin levels are low. The minor reduction in SWA 
in the first third of the night may be indicative of effects on core body temperature or other 
effects related to the pharmacokinetic properties of the drug. Temazepam and zolpidem on 
the other hand significantly reduced SWA as was expected, and this was observed in all three 
slow-wave ranges analysed for temazepam and in the 1.25-5.0Hz and the traditional slow-
wave range for zolpidem when compared with placebo. The effects of temazepam on the 
EEG were more pronounced than for the effects of zolpidem, this is likely due to the 
selectivity of zolpidem for GABAA receptors containing the alpha-1 subunit. 
 
Spectral analysis of the 8 traditional EEG frequency bands and 1Hz bins up to 32Hz revealed 
that both temazepam and zolpidem induced the well characterised EEG signature that is 
observed following administration of benzodiazepines and non-benzodiazepine z-drugs. Most 
notably, in accordance with previous research in healthy individuals (Bettica et al., 2012; 
Brunner et al., 1991; Dijk et al., 1989; Walsh et al., 2007) treatment with temazepam and 
zolpidem reduced power in the slow-wave, theta and alpha ranges compared to placebo, 
whereas prolonged-release melatonin did not significantly differ in any of the traditional EEG 
frequency bands compared to placebo. It has previously been observed by several groups that 
activity in the lowest slow-wave frequencies is enhanced or at least not reduced after 
zolpidem administration (Bettica et al., 2012; Brunner et al., 1991; Walsh et al., 2007), and 
such findings were also observed in the current study in the lowest 1Hz frequency bin during 
NREM sleep. This increase in activity in the 1Hz range may be related to the observed 
increase in visually scored SWS. It should be noted that this increase in SWS after zolpidem 
is accompanied by a very different spectral profile than the increase in SWS after sleep 
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deprivation. After the latter physiological manipulation enhancement of SWS and SWA is 
accompanied by enhancements of spectral power in a broad frequency range, up to 10 Hz, 
(Dijk et al., 1990b; Dijk et al., 1993); whereas after pharmacological intervention with 
zolpidem, activity in the range of approximately 2-11Hz is reduced (Bettica et al., 2012; 
Brunner et al., 1991; Walsh et al., 2007). The behaviour of very low frequency components 
of the EEG in response to hypnotics is also of some interest because reductions  of these  
EEG frequencies  or of delta activity encompassing these slow components  have been 
observed in chronic fatigue  syndrome (Le Bon et al., 2012) and insomnia (Bastien et al., 
2003; Merica et al., 1998), and these reductions  may  reflect abnormalities in sleep 
homeostasis in these individuals.  
 
In contrast to other studies (Brunner et al., 1991; Dijk et al., 1989; Walsh et al., 2007) no 
significant enhancement in the sigma frequency range (12.0-<15.0Hz) was observed 
following administration of zolpidem or temazepam when compared to placebo. However, 
visual inspection of the power density spectrum showed that there was a tendency for 
temazepam and zolpidem to increase power at 13Hz and 13-14Hz for temazepam and 
zolpidem respectively when compared to placebo; In addition,  statistically significant  
enhancement of sigma activity was not always observed (Dijk et al., 1989). The differences 
between our study and others’ could undoubtedly be related to age effects on the EEG, 
whereby EEG power decreases with age, particularly at frequencies below 14Hz (Landolt et 
al., 1996). Despite subjects being older in our study compared with most previous studies, the 
majority of the effects of the study medications on the spectral composition of the EEG were 
similar to those previously observed by others; in addition, the effects of temazepam and 
zolpidem on the EEG serve to indicate that the small effects of prolonged-release melatonin 
on the EEG cannot be due to a lack of sensitivity of the spectral analysis method or absence 
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of effects of hypnotics on the EEG of middle-aged participants. It should also be 
acknowledged that temazepam has a longer terminal half-life compared with zolpidem (3.5-
18.4h and 2.5h respectively) and this may have contributed to the more pronounced effects of 
temazepam on the entire night EEG power spectrum compared to zolpidem. The absence of 
major effects of prolonged-release melatonin administration on EEG power spectra is 
reminiscent of the effects of a dual orexin receptor antagonist, where neither the NREM nor 
REM sleep EEG was affected, however, measures of hypnotic efficacy such as latency to 
persistent sleep and total sleep time were significantly affected (Bettica et al., 2012). In our 
analyses we have used definitions for frequency ranges based on our previous work 
(Aeschbach et al., 1994; Aeschbach et al., 1997; Dijk and Czeisler, 1995) allowing 
comparison with these previous publications. These definitions are slightly different from the 
AASM manual (Iber et al., 2007) but our analyses with a 1Hz resolution of the EEG power 
spectrum (see Figure 3 and Figure 4) and the behaviour of the EEG in the low frequency 
range (see Table 2 and Table 3) provide a detailed description of the changes in the EEG, 
independent of the somewhat arbitrary frequency band definitions.  
 
Prolonged-release melatonin did not significantly affect PSG sleep measures compared with 
placebo. This is in accordance with the observations by others that exogenous melatonin 
administration either minimally or does not at all affect PSG sleep measures in healthy 
individuals (Cajochen et al., 1997; Wyatt et al., 2006) or insomnia sufferers (Luthringer et al., 
2009) when administered during the phase of endogenous melatonin secretion. It appears 
from studies in healthy individuals that exogenous melatonin administration only affects 
sleep when endogenous melatonin levels are low (Rajaratnam et al., 2004; Stone et al., 2000; 
Wyatt et al., 2006). Temazepam and zolpidem improved sleep by increasing TST, NREM 
sleep duration and sleep efficiency, amongst other variables. The observed increase in sleep 
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stage 4 sleep following zolpidem treatment compared with temazepam and prolonged-release 
melatonin, and an increase in SWS after zolpidem compared with prolonged-release 
melatonin, resembles the differential effects of zolpidem on the low-delta frequency band, 
even though the effects of zolpidem on the slow-wave and theta frequencies is very similar to 
the effects of temazepam. Spectral analysis revealed the complexity of the effects of these 
medications on the EEG and our data gives further support to the notion that spectral analysis 
is a more sensitive tool for assessing drug efficacy. 
 
There was significant subjective improvement of sleep quality following temazepam and 
zolpidem compared with placebo and prolonged-release melatonin on several of the SQQ 
questions. The morning KSS did not reveal any significant subjective differences between 
treatments and placebo and therefore suggests that there were no residual effects of treatment 
in the morning. Although we did not find that prolonged-release melatonin improved 
subjective sleep quality, it has been reported that prolonged-release melatonin is effective in 
the subjective improvement of insomnia in patients (Lemoine et al., 2007; Lemoine et al., 
2011; Lemoine and Zisapel, 2012; Wade et al., 2007; Wade et al., 2010; Wade et al., 2011). 
The present study was powered to detect effects on EEG power spectra in the slow-wave 
frequency ranges and not to detect effects on PSG or subjective measures of sleep and 
therefore the results from these variables should be interpreted with caution.  Nevertheless, 
the dissonance observed between our prolonged-release melatonin results in healthy 
participants and those reported in insomnia patients implies that it may be informative to 
conduct further PSG studies of the effects of melatonin in well-screened insomnia patients. 
 
Whilst it is beyond the scope of the research presented here to advise upon treatment options 
for insomnia in older people, the well documented impracticalities of the use of 
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benzodiazepines and non-benzodiazepine z-drugs including withdrawal symptoms and 
rebound insomnia, provide substantial reason to consider other treatment options for 
insomnia. In addition, prolonged-release melatonin use is not associated with the residual 
effects which are often observed following administration of benzodiazepine and other 
allosteric modulators of the GABAA receptor. A study of the effects of prolonged-release 
melatonin in healthy men and women aged 55 years and over reported that prolonged-release 
melatonin was not associated with impaired memory recall, driving performance or 
psychomotor function (Otmani et al., 2008). Along these lines, prolonged-release melatonin 
has been recommended as a first line therapy in older insomnia patients (Wilson et al., 2010), 
and a large surveillance study recently reported that following withdrawal from Circadin®, 
sleep quality and alertness remained improved and rebound insomnia incidence was low for 
older insomnia patients (Hajak et al., 2014). Whilst we only reported very few changes in the 
EEG induced by prolonged-release melatonin, greater responses to exogenous melatonin 
administration have been observed at other times of day and given the role of melatonin in 
sleep regulation, there would be a rational basis for pursuing medications that target these 
receptor systems in the development of treatments for insomnia. The exact physiological 
roles of the melatonin receptors is not well understood and  indeed, further understanding of 
the mechanisms by which melatonin receptor agonists exert their effects is required in order 
to develop nocturnally beneficial therapies for insomnia that target these receptors. Newer 
approaches to melatonergic therapies appear to be focussing on the development of drugs 
which target several receptor systems in order to improve efficacy (Carocci et al., 2014).  
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